BOWAVE Pharmaceuticals Receives IND Approval in China for Third siRNA Candidate BW-20805 Targeting Hereditary Angioedema
Argo
RNAi Drug Developer
Recently, according to the announcement on the CDE official website, Hangzhou Bolin Pharmaceutical Technology Co., Ltd., a subsidiary of Argo, has submitted an application.siRNA Drug "BW-20805 Injection"ObtainClinical Trial Implied Permission(Application No.: CXHL2300824)，For the treatment of hereditary angioedema(HAE)。
Source: CDE Official Website
Hereditary Angioedema（HAE）It is a rare and severe autosomal dominant genetic disease characterized by recurrent episodes of self-limiting tissue edema. Currently, there is only one monoclonal antibody drug for this disease available in China — Lanadelumab Injection from Takeda Pharmaceuticals.
BW-20805 is the third siRNA drug approved for clinical trials in China this year by Argo.In addition, the two siRNA drugs previously approved for clinical trials areBW-00163AndBW-00112，Their indications are hypertension and dyslipidemia, respectively.
About Argo
Argo is focused on the development of a new generation of siRNA drugs, with years of professional experience in all aspects of RNAi drug development, including nucleic acid sequence design, chemical modification, GalNAc delivery technology, extrahepatic delivery technology, oligonucleotide synthesis, and CMC.
The company was founded in 2021 by Dr. Dongxu Shu and Dr. Pengcheng Shao, scientists with extensive experience in siRNA drug development.(Previously at well-known companies such as Arrowhead)At its inception, it secured tens of millions in angel round funding from Apricot Capital, followed by an over 400 million yuan A-round financing with investments from multiple well-known institutions.
It is reported that the company currently has several pipelines in the preclinical research stage of new drug application.（IND-enabling）Phase, during which all three drugs have entered Phase 1 clinical trials in China, the U.S., and Australia.
E.N.D
Recommended articles from previous issues:
New Bio Completes 50 Million Pre-B Round Financing
Dinayuan Sheng Completes Pre-A+ Round Financing with Exclusive Investment from Panlin Capital
Reaching 100 Billion by 2025! China Accelerates Cell Therapy Development
Analysis of the Immunogenicity of mRNA Vaccines
Nine Skies Biopharma's AAV Ophthalmic Gene Therapy Drug Approved by China's NMPA for Clinical Trials
Zuckerberg Invests $250 Million in Cell Industry, with a Vision Beyond Current Medical Standards!
China's CT Tianqing siRNA New Drug Approved for Clinical Trials, Targeting Chronic Hepatitis B
BDG Milestone | BDG's Lentiviral Vector Thalassemia Gene Therapy IND Accepted by CDE
FDA Allows In Vivo Gene Editing Therapy Product to Proceed to Phase III Clinical Trials
Legend Biotech: BCMA CAR-T Sales Reach $340 Million in the First Three Quarters
Central China's First Stem Cell Bank Established at Tongji Hospital
History of Clinical Development in Gene Therapy
NMPA: Over 100 Cell and Gene Therapy Products Approved for Clinical Trials
2023 Nobel Prize in Physiology or Medicine Awarded to mRNA Vaccine Technology
Characteristics and Application Prospects of Circular RNA (I)
Gene Editing Therapy Industry Research Report
1.5 Billion! Shenzhen Plans to Establish a Cell and Gene Industry Fund